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S. C. Weight* and M. L. Nicholson 
University Department of Surgery, Leicester General Hospital, Gwendolen Road, Leicester LE5 4PW, U.K. 
Background: Nitric oxide (NO) is a ubiquitous molecule with a role in both normal homeostasis and pathophysiological 
processes. However, the role it plays in renal ischaemia reperfusion injury is a matter of some contention. 
Method and Results: This paper prdcis the biology and biosynthesis of NO before concentrating on the function of NO 
in renal ischaemia reperfusion injury. What emerges is a picture of some clarity about the normal physiological role of 
NO but some discord regarding the generation and function of postischaemic nitric oxide. Some of the reasons for this 
are explored in more detail. 
Conclusions: Clarity on the precise effect of postischaemic NO will remain elusive without he in vivo measurement of 
NO in experimental models. 
Introduction 
Renal warm ischaemia reperfusion injury in clinical 
practice is a sequela of both systemic hypoperfusion 
with subsequent circulatory resuscitation and local 
renal hypoperfusion following either aortic cross- 
clamping or renal transplantation. I  abdominal aortic 
aneurysm (AAA) surgery the proximal extent of the 
neck of the aneurysm sac in relation to the renal arteries 
has an important bearing on subsequent morbidity and 
morality. Cross-clamping the juxtarenal or suprarenal 
aorta is associated with an increased perioperative 
cardiac and pulmonary demand in addition to an 
ischaemic insult sustained by the kidneys and possibly 
the visceral organs and spinal cord. Whilst the majority 
of AAA repairs allow for infrarenal cross-clamping 
the consequent altered haemodynamics still results in 
a significant decrease in renal blood flow. 1 Release of 
the aortic clamp therefore leads not only to both a 
systemic reperfusion i jury, 2 which will affect he kid- 
ney as a highly vascularised organ, but also a local 
renal reperfusion injury. 
A lack of suitable organs for transplantation from 
traditional sources has led clinicians to seek al- 
ternatives, in part from non-heart-beating donors 
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(NHBD). 3 The results are encouraging, although graft 
survival is poorer and both primary non-function and 
delayed graft function more prevalent than in kidneys 
from cadaveric donors. This is a consequence of the 
prolonged warm ischaemic insult before renal cooling 
can take place. 4-6 
Ischaemia reperfusion injury is a complex, inter- 
related sequence of events involving the vascular endo- 
thelium and activated leucocytes. During the ischaemic 
phase the endothelium is primed both to produce 
free radicals and secrete chemoattractants with the 
resultant influx of neutrophils on reperfusion amp- 
lifying the free radical-induced damage. 7'8 Whilst the 
role of free radicals and neutrophils in post-ischaemic 
damage has been delineated, the place of nitric oxide 
is less certain. 
Research into the clinical role of nitric oxide has 
expanded ramatically since Furchgott and Zawadski 9 
demonstrated in 1980 that acetylcholine-dependent 
vasodilation (i.e. receptor-dependent) was effected by 
a non-prostanoid, endothelium-dependent factor 
which was termed endothelium derived relaxing factor 
(EDRF). Work on identifying this substance culminated 
7 years later when Palmer et al. 1° showed that EDRF 
was nitric oxide (NO) derived from the metabolism 
of L-arginine. 11 
Beyond the role of NO as EDRF, it is also implicated 
in the modulation of platelet function, neuro- 
transmission, ~2inhibition of neutrophil chemotaxis, 
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Table I. Classification and properties of nitric oxide synthase. 
Form Isoform Principal ? Basal no Endogenous Endogenous 
source production inducers i~hibitors 
Ia Brain 
ACh 
Ib EC ATP 
Constitutive Yes ADP ADMA 
Ic PMN Thrombin 
SS 
III EC AA 
II Cytokines IL-4/IL-10 
Inducible Macrophage No Endotoxin GC 
W 
Abbreviations: EC= endothelial cells; PMN = polymorphonuclear leucocytes; pM = ipicomolar; nM = 
nanomolar; ACh = acetylcholine; ATP = adenosine 5'-triphosphate; ADP = adenosine 5'-diphosphate; 
SS ~ shear stress; AA = excitatory amino acids; ADMA = asymmetric dimethyl arginine; IL-4 = inter- 
leukin-4; ILq0 =interleukin-10; GC=glucocorticoids. 
adherence and activation, h3neutrophil cytotoxicity ~4 1000-fold greater than cNOS (nanomolar ather than 
and immunomodulat ion following an allograft. 15 picomolar concentrations). 25 
Clinical biology: biochemistry and biosynthesis 
Nitric oxide is a free radical 16 formed during the 
conversion of L-arginine to L-citrulline. It has a short 
half-life in biological solutions, primarily due to: (i) 
oxidation to nitrate and nitrite, ~7 (ii) quenching with 
the superoxide radical TM and (iii) binding to haem- 
containing proteins with Fe-S sites such as oxy- 
haemoglobin. 19 Oxidation of the terminal guanidino 
nitrogen of L-arginine 2° occurs under the control of 
the enzyme nitric oxide synthase (NOS) with the sub- 
sequent elimination of eqimolar amounts of NO and 
superoxide (02-) and generation of L-citrulline. 2~ In 
the absence of L-arginine, however, NOS will continue 
to generate the superoxide anion. 22 
Four main isoforms of NOS have been identified 
(Table 1). Two of these are constitutive (cNOS) and 
two inducible (iNOS) enzymes. The constitutive form 
of the enzyme is responsible for a continual, basal 
release of NO, although this production can be up- 
regulated. It is membrane bound and possibly linked 
to the cytoskeleton which accounts in part for the 
regulatory effect on endothelial NOS of vascular sheer 
stress and f l ow.  23 The constitutive isoforms are de- 
pendent on calcium and calmodulin for their ac- 
tivation, whereas calmodulin is already bound to 
activated iNOS which therefore remains independent 
of the free calcium concentration. Inducible NOS is a 
free cytosolic enzyme which is basally quiescent but 
once induced is permanently active for the life of the 
enzyme 24 (up to 24 h) and produces NO in amounts 
Nitric oxide and renal physiology 
The vascular endothelium is one of the prime effector 
sites for NO with endothelial cells able to generate 
NO via both cNOS and iNOS. 26 Furthermore, the 
underlying smooth muscle cells (SMC) can also syn- 
thesise iNOS under conditions of large-scale cytokine 
release such as sepsis or the systemic inflammatory 
response. 23Vasodilation is mediated via soluble gu- 
anylyl cyclase (sGC), which is activated by haem group 
nitrosylation and produces cyclic guanylate mono- 
phosphate (cGMP). Kinases dependent on this sec- 
ondary messenger phosphorylate SMC proteins 
leading to relaxation. 27
A major role for NO in normal renal physiology 
has been established with both main forms of NOS 
expressed. Their relative distribution varies within the 
kidney, with the constitutive form of NOS pre- 
dominately localised in the preglomerular vasculature, 
macula densa (MD) and collecting duct whilst iNOS 
has a more general distribution with the exception of 
the vessels and MD 28 (Table 2). 
Utilising NOS blockers and micropuncture tech- 
niques, it has proved possible to determine the role of 
NO in normal renal homoeostasis. Correlating closely 
with the distribution of the constitutive isoform of the 
enzyme, NO antagonises the vasoconstrictive effect of 
angiotensin II on the afferent arteriole 29 and helps to 
maintain the glomerular filtration rate (GFR), renal 
blood flow 3°'3~ and sodium regulation. 32The interaction 
of NO and renin remains unclear, however, for whilst 
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Table 2. Renal distribution and semi quantification (using PCR) 
of cNOS and iNOS. 
Site cNOS iNOS 
Preglomerular vessels + - 
Golerulus + + + 
Macula densa + + + + - 
Proximal tubule - + + 
Loop of Henle + + + 
Distal tubule - + + 
Cortical collecting duct + + + 
Medullary collecting duct + + + + + + 
one study using (intravenously) anaesthetised rats 
suggested NO may act in a paracrine fashion within 
the glomerulus to stimulate the release of renin, 33 
another study 32 found NOS blockade increased plasma 
renin activity (PICA) in conscious dogs. The effect of 
certain anaesthetic agents on NOS may be one cause for 
such discrepancies, 34 although inhalational anaesthesia 
has been demonstrated not to affect NOS activityY 
Nitric oxide and renal ischaemia reperfusion injury 
Background and theory. The classical model of ischaemia 
reperfusion injury whereby ischaemia "primes" the 
tissue for oxygen-derived free radical (OFR) generation 
during the reperfusion phase is now clearly not the 
whole story. Studies on isolated proximal tubules have 
demonstrated that early in the ischaemic phase NOS 
activity is increased with NO generation apparently 
maximal by 10 min.  36 The dynamic equilibrium be- 
tween NO and the OFRs generated during re- 
oxygenation may thus be critical in determining the 
degree of postischaemic damage. A reaction between 
these species may result in either quenching of both 
or alternatively act as the substrate for further OFR 
production. 
Probably the most important interaction is between 
NO and superoxide (02-)  37 which react rapidly (rate 
constant 109 / ms) 3s with the ultimate limination of both 
radicals. Such quenching will be cytoprotective 39 only 
if the product of this reaction is less toxic than the con- 
stituents. The product of this reaction is, in fact, per- 
oxynitrite (ONOO-), a short-lived oxidant species that 
is rapidly protonated to HOONO which then decays to 
generate the highly toxic hydroxyl radical (overall half- 
life of less than 2 s at pH 7.4). 4°'41 The temporal sep- 
aration of NO and 02- during ischaemia and re- 
perfusion cannot be discounted either. Whether or not 
the interaction of these two radicals is ultimately toxic or 
protective, it appears that NO alone is generated during 
ischaemia. Throughout this unopposed phase NO may 
well damage the actin cytoskeleton 42 through ATP de- 
pletion in addition to directly altering DNA 43 and in- 
hibiting the subsequent repair. 44 Renal epithelial cell 
adhesion may also be impaired by actin degradation 
affecting integrin-ligand binding. 45'46 
It would thus be easy to conclude that postischaemic 
NO is cytotoxic, except hat in certain circumstances 
NO-mediated nitrosylation has been shown to have a 
cytoprotective effect. One target for HOONO is the cell 
membrane which is peroxidised leading to membrane 
pump inactivation and ultimately cell death. This lipid 
peroxidation ispropagated by the formation of peroxyl 
radicals and thus their inactivation, via nitrosylation to 
alkyl peroxynitrate (LOONO) helps to maintain cellular 
integrity; especially when the subsequent metabolism 
of LOONO does not generate further free radicals. 47 
Further evidence of the cytoprotective effect of NO is 
seen in its interaction with leucocytes. A number of 
post-ischaemic mediators, including xanthine oxidase, 
platelet activating factor, thromboxane and leu- 
kotrienes, are involved in leucosequestration. These 
neutrophils then adhere, activate and migrate under 
the control of adhesion molecules, most notably the B- 
integrins. Both these (the CDll /CD18 complex in par- 
ticular) and the matrix proteins are integrally involved 
in the subsequent respiratory burst. 4s The involvement 
of nitric oxide in the proteolysis of B-integrin has been 
demonstrated, 49 as has the effect of NO on the extra- 
cellular matrix. 5° Thus, by interfering with the neutro- 
phil respiratory burst NO should help ameliorate post- 
ischaemic renal damage and this has been shown ex- 
perimentally. 51,52 
Several possibilities emerge for the role of NO during 
ischaemia nd reperfusion, and it is undoubtedly too 
simplistic to suggest NO is either solely cytotoxic or cy- 
toprotective. Whilst the results of in vitro studies uggest 
the former in vivo work demonstrates that protective 
effect of NO on overall postischaemic renal function. Part 
of this discrepancy may be attributable tothe vasoactive 
function of NO in maintaining microvascular perfusion 51 
in addition to the complex interaction of cytokines and 
leucocytes absent from the in vitro models. Furthermore 
the balance of free radicals, especially NO and 02 ,  dur- 
ing reperfusion may be critical in determining the degree 
of eventual damage, with an excess of NO over O2- in the 
post-ischaemic tissue having an overall cytoprotective 
effect o counteract ONOO- toxicity. 53 Such a balance can 
be achieved experimentally by manipulating the post- 
ischaemic levels of 02- and NO. 
Experimental evidence. One of the first investigations 
was undertaken by Lieberthal et al. ~ on isolated rat 
kidneys and they concluded that NO activity was 
impaired following IRI. In contrast, Rivas-Cabagero 
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et al. ss cultured glomeruli from ischaemic rat kidneys 
and measured nitrite production. This demonstrated a 
significant rise in NO production after I h of ischaemia 
followed by 24 h reperfusion (prior to glomerular har- 
vest) when compared to either 1 h ischaemia/1 h re- 
perfusion or the control (no ischaemic insult). This is 
at odds with the work of Yacoob et al. 21 who found 
NO actual increased during renal proximal tubular 
ischaemia before falling towards normal levels upon 
reoxygenation. 
Both Chintala eta]. 56 and Kin eta]. 57 concluded that 
endogenous NO production is important in main- 
raining postischaemic renal function following the first 
2 and 24 h respectively of reperfusion i jury. A similar 
picture emerges from the work of Conger et al. 58 and 
Cristol et al. 59 in assessing the role of endogenous and 
augmented (by L-arginine infusion) NO, respectively, 
with an additional insight into NOS activity. Conger 
et al. 58 used a renal artery infusion of norepinephrine 
to induce ARF and then measured renal blood flow 
(as the index of NO activity) following the infusion of 
L-NAME (an iNOS and cNOS inhibitor), amino- 
guanidine (an iNOS inhibitor) and SNAP (a NO 
donor). They concluded that 1 week after inducing 
ARF the activity of renal NOS was already maximal 
and therefore exogenous attempts to stimulate NO 
production were futile. Furthermore, when correlating 
the effects of iNOS blockade with immuno- 
histochemical studies it appeared that iNOS expression 
was not upregulated. 
The model of Cristol et al. 59 used a rather more 
direct method of inducing renal ischaemia (renal artery 
occlusion) and demonstrated a similar decline in RBF 
in response to L-NAME. They also used a more soph- 
isticated process to elucidate which form of NOS was 
responsible for postischaemic NO generation (al- 
though they do not determine if this is upregulated 
over baseline). Briefly, by using tritiated arginine as 
the substrate for NO production the consequent (3H)- 
citrulline generated can be quantified by scintillation 
counting; and by either adding or chelating calcium 
the relative roles of cNOS (calcium-dependent) and 
iNOS (calcium-independent) can be assessed. They 
concluded that the constitutive but not inducible form 
was responsible for postischaemic NO generation. In 
contrast to this, Noiri et al. 6° used antisense oligo- 
nucleotides to selectively knock-down iNOS. When 
directed at renal iNOS the postischaemic njury was 
ameliorated whilst knock-down of vascular SMC iNOS 
exacerbated the deterioration i renal function. 
There is, however, no more unanimity on the role 
of NO in renal ischaemia reperfusion injury that in 
other organ models and L6pez-Neblina etal. 61 conclude 
the antithesis of this. Using a rat model of renal warm 
ischaemia they found no role for endogenous NO in 
maintaining renal function but exogenous NO (via 
SNAP) not only improved function but also the mor- 
phological picture and survival. 
Attempts to maximise NO production have tended 
to focus on the provision of L-arginine as a precursor 
and hence enhancer of NO generation rather than 
through the use of nitric oxide donors such as SNAP. 
Once again, however, the evidence for an associated 
increase in NO is often assumed rather than affirmed 
and whilst L-arginine can under certain circumstances 
enhance NO production this has not been shown in 
the postischaemic kidney. For example, Dagher et al. 62 
demonstrated a beneficial effect on glomerular fil- 
tration and tubular function from a L-arginine infusion 
prior to the onset of ischaemia, whereas Conger et aI. 58 
found that infusion during ischaemia conferred no 
benefit. The conclusion that the former is the result of 
augmented NO generation is unproven as no measure 
of NO was made. Certainly the reaction kinetics of 
L-arginine-NO do not suggest substrate availability 
would be rate limiting 2s and this has been dem- 
onstrated clinically by MacAllister eta]. ,  63 albeit not 
under pathophysiological conditions. Furthermore, 
they showed that L-arginine, in the massively supra- 
physiological doses (x20 normal plasma con- 
centration) commonly achieved in such studies, caused 
elevated levels of hormones including insulin, glu- 
cagon and prolactin. These may be responsible for 
some of the vascular effects attributed to the 
L-arginine-NO axis. 
Nitr ic oxide, prostanoids and the kidney 
Somewhat reminiscent of nitric oxide synthase, one of 
the enzymes responsible for the production of pro- 
stanoids exists in both a constitutive and inducible 
form. Cyclooxygenase 2 (COX 2) is the inducible en- 
zyme which is expressed principally on monocytes 64 
and endothelial cells 65. Vasodilator prostanoids uch 
as prostacyclin (PGI2) are important in maintaining 
RBF in the postischaemic kidney s9 and recent evidence 
points to a linkage between NO and these prostanoids. 
Using a model of renal inflammation Salvemini et 
al. 6° have shown that both endogenous and exogenous 
NO can induce COX 2 which acts to support the 
inflammatory process. However, measuring 6-keto- 
prostaglandinl~ (the stable metabolite of PGI2) and 
nitrite in a model involving both in vitro work on a 
macrophage c ll line and also in vivo renal experiments 
Swierkosz et al. 67 came to very different conclusions. 
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Whilst concurring that iNOS and COX 2 can be co- 
induced and also that COX would appear to act as a 
receptor for NO, they concluded that both endogenous 
and exogenous NO inhibits the expression of COX 2 
in vitro. It appears that low levels of NO may potentiate 
the activity of COX 2 whilst high levels are inhibitory. 
Although no renal NO-COX interaction was apparent 
in vivo this was not an ischaemic reperfusion model 
which may be important for it has recently been dem- 
onstrated 6sthat peroxynitrite rapidly and irreversibly 
blocks PGI2 biosynthesis whilst NO (or the superoxide 
radical) alone has no effect. 
Conclusion 
Since EDRF was first identified as nitric oxide in 1987 
there has been a plethora of research delineating the 
biosynthesis and physiology involved in NO biology. 
Whilst the enzyme responsible for synthesising NO is 
present in many tissues, this article focuses on the 
kidney and in particular the importance of nitric oxide 
in maintaining postischaemic renal function. However, 
this is not presented in isolation but as part of the 
more global ischaemia reperfusion injury in order to 
facilitate the inevitable abridgement of so intricate a 
subject. 
In summary, nitric oxide can be seen to be a simple 
molecule involved in a complex sequence of events 
both physiologically and pathophysiologically during 
ischaemia nd reperfusion. What is not so clear is the 
precise effect of IRI on NO production in the kidney 
and whether it has a predominately protective or 
injurious role. The results of in vivo and in vitro studies 
appear often at variance and clarity will remain elusive 
until NO is directly measured rather than judged 
empirically. 
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